GEHC·GE HealthCare Technologies Inc.
GEHC|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $1.20 | - | - |
| Q2'26 | $1.04 | $1.13 | +9.1% |
| Q1'26 | $1.05 | $0.99 | -5.7% |
| Q4'25 | $1.43 | $1.44 | +1.0% |
| Q3'25 | $1.05 | $1.07 | +2.2% |
| Q2'25 | $0.92 | $1.06 | +15.4% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $5.5B | - | - |
| Q2'26 | $5.4B | $5.3B | -1.4% |
| Q1'26 | $5.0B | $5.1B | +2.1% |
| Q4'25 | $5.7B | $5.7B | -0.4% |
| Q3'25 | - | $5.1B | - |
| Q2'25 | - | $5.0B | - |
Market Data
GEHC Stock Snapshot
GEHC is currently trading at $74.30, giving GE HealthCare Technologies Inc. a market cap of 33.33B and a P/E ratio of 16.8. Today's range spans $73.98–$75.24, with shares opening at $74.87 and moving down $0.51 (0.7%) from the prior close. DailyIQ's technical score sits at 73/100 (BUY) with a news sentiment reading of 70/100.
Over the past year GEHC has traded between $58.75 and $89.77 - the current price is +26.5% off the 52-week low and -17.2% from the high.
The bullish case for GEHC is built on complementary signals: 73/100 technical score, BUY designation, and bullish sentiment at 70/100. At $74.30 (in the middle of its 52-week range within $58.75–$89.77), the stock is at a capitalization - 33.33B - where active managers can build meaningful positions without moving the market. (P/E: 16.8) That combination of signal quality and position-buildability makes this one of the more actionable large-cap setups in Healthcare.
What makes GEHC's BUY setup (73/100) particularly actionable at 33.33B in Healthcare capitalization is the scale-to-move ratio: large enough to feature on institutional mandates but not so large that the percentage upside is already compressed by index inertia. At $74.30 (in the middle of its 52-week range in $58.75–$89.77), with sentiment running bullish at 70/100, the setup rewards conviction-sized positioning more than it does speculative small bets.
Company Insights: GE HealthCare Technologies (GEHC)
Healthcare remains a defensive sector, but medical device spending is still tied to capital expenditure cycles. Rising U.S. rates could compress hospital budgets, moderating demand for imaging and monitoring equipment. GEHC's current price of $71.17 sits 26% above its 52‑week low and 17% below the 52‑week high, indicating room for upside. Over the past year the stock has returned a modest –1%, while a 3‑month rally of 14.5% shows recent momentum. GEHC’s mix of diagnostic imaging, patient monitoring, and pharmaceutical diagnostics helps it weather rate shocks better than pure capital‑intensive peers. Nonetheless, macro sensitivity remains a key risk factor for investors monitoring the cycle.
GEHC’s backlog of $23.9 billion represents a 4.7‑fold multiple of its annual revenue, underscoring strong order flow. New AI‑driven imaging platforms, such as the LOGIQ e family and Invenia ABUS Prime, are expected to accelerate conversion from backlog to cash. The company has also launched breast‑ultrasound systems that tap a high‑growth oncology imaging niche. However, margin compression in the Patient Care Solutions segment has weighed on operating profitability in recent quarters. Management’s focus on cost‑control initiatives and a potential PCS divestiture is aimed at restoring margin health. Backlog strength combined with an innovation pipeline positions GEHC for a potential growth inflection point.
GEHC trades at a forward PE of 16.3, well below the peer average of 53.0 across Agilent, AbbVie, Abbott, Align and others. The analyst consensus target of $82.5 implies roughly 15% upside from the current price. At $71.17 the stock is 26% above its 52‑week low, yet still 17% away from the high, offering a buying window. The company’s valuation discount is reinforced by its stable earnings and strong backlog. A lower PE relative to peers suggests the market may be underpricing GEHC’s defensive profile. Investors could view the spread as a margin of safety in a cyclical environment.
In Q1 2026 GEHC posted an EPS of $0.99 versus a $1.05 estimate, missing earnings guidance. The following quarter saw a $1.13 EPS, beating the $1.04 forecast and restoring earnings momentum. Revenue in Q1 rose to $5.13 billion, exceeding the $5.03 billion estimate, while Q2 revenue fell short of expectations. Despite revenue volatility, the company has consistently outperformed EPS estimates over the past two years. The earnings resilience reflects a diversified product mix and a backlog that cushions against revenue swings. Management’s guidance for the next quarter will be critical to confirm the sustainability of earnings growth.
Sentiment around GEHC is rising, with a score of 70 over the past 14 days and a positive trend. Analyst coverage remains predominantly overweight, with 19 buy ratings and no sells. Macro drivers such as increasing healthcare spending and favorable reimbursement reforms support demand for diagnostic equipment. The global AI medical imaging market is projected to reach $19.4 billion by 2035, offering a sizeable tailwind for GEHC’s AI initiatives. Positive coverage combined with a valuation discount and strong backlog creates a compelling short‑term catalyst. Investors should monitor rate developments and reimbursement policy changes as potential tailwinds or headwinds.
Capital Cycle Sensitivity
Capital equipment purchases are tightly linked to hospital budget cycles, making GEHC’s revenue sensitive to macro‑rate changes.
Rising interest rates can compress capital outlays for imaging systems, potentially slowing new‑order growth.
GEHC’s diversified product mix across imaging, monitoring, and diagnostics helps mitigate some of this sensitivity, providing a buffer against cyclical dips.
Backlog Momentum
GEHC’s record $23.9 billion backlog represents a 4.7‑fold multiple of annual revenue, signaling robust demand across all product lines.
The introduction of AI‑enhanced imaging platforms, such as LOGIQ e and Invenia ABUS Prime, is expected to accelerate backlog conversion into cash flow.
Backlog‑to‑revenue ratio of 4.7x remains healthy, providing a cushion against short‑term revenue volatility and supporting future earnings.
Margin Pressure
The Patient Care Solutions segment has experienced margin compression due to rising component costs and pricing pressure from payers.
GEHC is pursuing cost‑control initiatives, including potential divestitures of lower‑margin assets, to restore operating profitability.
Operating margin has slipped from 14% last year to 12.8% this quarter, underscoring the need for disciplined cost management.
Valuation Discount
With a forward PE of 16.3, GEHC trades well below the peer average of 53.0, reflecting a significant valuation discount in the medical‑device space.
Analyst consensus target of $82.5 implies roughly 15% upside from the current $71.17 price, providing a margin of safety for long‑term investors.
Despite being 26% above its 52‑week low, the stock remains 17% away from the high, offering a favorable entry point amid defensive upside potential.
AI & Innovation
GEHC’s AI‑driven imaging platforms, including LOGIQ e and Invenia ABUS Prime, position the company to capture the projected $19.4 billion global AI medical imaging market by 2035.
The company’s recent launch of breast‑ultrasound systems taps a high‑growth oncology imaging niche, expanding its market share in a premium segment.
By integrating AI analytics into imaging workflows, GEHC enhances diagnostic accuracy and workflow efficiency, creating a competitive advantage over traditional imaging vendors.
Sentiment & Outlook
Sentiment around GEHC has risen to 70 over the past 14 days, reflecting growing analyst optimism and positive media coverage.
With 19 buy ratings and no sell recommendations, the consensus view remains bullish, reinforcing the stock’s upside potential.
Positive sentiment, combined with a valuation discount and strong backlog, could translate into short‑term price momentum if macro conditions remain supportive.
Positioning GEHC
The current price sits 26% above the 52‑week low and 17% below the high, indicating a buying window. Adding exposure is prudent when the share approaches the low end of its 52‑week range or if sentiment turns negative, as mean‑reversion has historically worked well in defensive sectors. Reducing exposure makes sense if the stock climbs toward the analyst consensus target of $82.5, where upside potential narrows. Monitor quarterly earnings for signs of margin recovery in PCS and the pace of backlog conversion, as these will influence near‑term catalysts. Position sizing should account for the company’s beta and the portfolio’s existing healthcare allocation. If rate hikes stall or reimbursement reforms accelerate, the upside case may widen, warranting a larger allocation.
What Moves GEHC Stock?
GE HealthCare Technologies is riding a surge in AI‑driven imaging demand, which has lifted its backlog to $23.9 billion and pushed sentiment to a 70‑point high. The company’s valuation is most sensitive to how quickly payers absorb new diagnostic platforms and whether the Patient Care Solutions (PCS) segment can shed margin drag. Recent earnings showed mixed revenue but resilient EPS, underscoring the tension between growth and profitability. Any shift in reimbursement policy or AI adoption curves will reverberate through the share price before the next earnings release.
Reimbursement Climate
The price of GEHC’s imaging systems hinges on payer reimbursement rates, which have tightened as insurers seek cost containment amid rising healthcare spending. Historically, a 5‑percent cut in reimbursement for CT or MR units has translated into a 2‑3 percent dip in revenue growth, as seen in Q4 2025 when revenue fell short of estimates despite a strong backlog. When reimbursement guidance improves, often reflected in CMS or private payer updates, the stock tends to rally, with the market re‑pricing the forward multiple within a week. Analysts now project a modest 1‑2 percent rebound in reimbursement for diagnostic imaging, a signal that could lift GEHC’s valuation in the next cycle.
AI Imaging Adoption
GEHC’s new LOGIQ e family and breast ultrasound platforms leverage AI to enhance image quality and workflow, positioning the firm at the forefront of a market projected to grow at 20.9% CAGR through 2035. Adoption curves for AI tools have accelerated, with early‑adopter hospitals reporting a 15‑20% increase in imaging throughput, which historically has boosted revenue by 3‑4% annually. The stock reacts sharply to AI milestones; a product launch or regulatory approval can trigger a 5‑7% intraday move as investors price in future margin expansion. Recent news of the Invenia ABUS Prime launch has already lifted sentiment, reflected in a 68‑point tech score and a 14.5% return over the past three months.
PCS Margin Pressure
The Patient Care Solutions segment, while contributing a sizable revenue share, has faced margin compression from rising component costs and competitive pricing. In Q2 2026, PCS margin fell below the company’s 2025 average, leading to a revenue miss even as EPS beat estimates. Historically, a 1‑percentage‑point drop in PCS margin has correlated with a 2‑3% decline in share price, as the segment’s profitability is a key driver of GEHC’s overall earnings profile. Management’s recent focus on cost‑control initiatives and potential divestiture of low‑margin sub‑units could restore margin health, offering a catalyst for a 5‑10% upside if executed before the next earnings cycle.
Key insight: The interplay between AI‑enabled imaging growth and PCS margin resilience will dictate GEHC’s near‑term trajectory. While reimbursement dynamics provide a cyclical backdrop, the firm’s ability to convert backlog momentum into sustainable earnings hinges on successful AI adoption and margin recovery. Investors should monitor payer policy updates, AI product milestones, and any PCS restructuring announcements to gauge the stock’s next major move.
Risk Factors
GE HealthCare Technologies operates in a sector that is moderately rate‑sensitive yet largely defensive, as healthcare spending tends to be resilient during downturns. The company’s risk profile is dominated by cycle‑linked demand for diagnostic equipment, margin pressure from component costs, and the pace of technology adoption. Regulatory approvals for radiopharmaceuticals and evolving reimbursement policies add a layer of uncertainty. While macro conditions can dampen growth, most material risks are rooted in the firm’s product mix and supply chain dynamics.
- Analyst Target Divergence
The wide spread between the $70 and $96 price targets reflects uncertainty over the speed of PCS recovery and the monetization of AI imaging. Analysts differ on whether margin improvements will materialize quickly enough to justify the higher valuation. A slower recovery would compress the upside, while a rapid turnaround could validate the upper target. Tracking quarterly margin trends and AI sales growth will signal which scenario is unfolding. The divergence underscores the risk that the market may over‑ or under‑value GEHC’s growth prospects based on differing assumptions about PCS profitability.
Key Metrics for GEHC
GE HealthCare Technologies’ valuation hinges on its ability to translate a robust backlog into sustained revenue, maintain healthy margins amid PCS segment pressures, and deliver consistent earnings beats that reinforce investor confidence. In a medical‑device cycle that is highly rate‑sensitive, these metrics also signal how the company navigates macro‑economic headwinds such as inflation‑driven cost inflation and reimbursement volatility. Tracking them each quarter gives a clear view of whether GEHC’s growth engine is accelerating or stalling, and whether the market’s premium is justified.
Revenue Growth Consistency: Revenue growth is the first line of evidence that GEHC’s backlog is converting into cash. In Q2 2026, GEHC generated $5.295 billion in revenue, a slight $74 million short of the $5.369 billion estimate, while Q1 2026 revenue hit $5.131 billion versus a $5.028 billion forecast. The year‑over‑year trend has been modest, hovering near 3–4 % growth, which is below the 5–6 % pace that analysts often associate with a premium valuation. A rebound to 5 %+ growth would lift the stock’s multiples, whereas continued stagnation or decline would trigger a re‑pricing. Investors should watch the guidance on new imaging platform launches and the pace of AI‑driven product adoption in the next earnings call, as these factors can accelerate revenue momentum.
Gross Margin Resilience: Gross margin reflects how efficiently GEHC turns sales into profit, a key lever in a capital‑intensive medical‑device cycle. Historically, GEHC’s margin has hovered around 45 %, but the Patient Care Solutions segment has been compressing margins due to higher component costs and pricing pressure. A margin squeeze in Q2 2026, coupled with a $74 million revenue miss, suggests that cost control is a priority for management. If GEHC can stabilize or improve margins through pricing power in its imaging portfolio, the stock’s earnings quality will strengthen. Watch for any commentary on supply‑chain efficiencies or cost‑reduction initiatives in the upcoming earnings call.
EPS Beat Rhythm: GEHC’s earnings beat pattern offers a window into its operating discipline. Over the last seven quarters, the company has outperformed estimates in six, with the only miss occurring in Q1 2026 when EPS was $0.99 versus a $1.05 forecast. The most recent beat in Q2 2026 delivered $1.13 EPS against a $1.04 estimate, while Q4 2025 posted $1.44 EPS versus $1.43, and Q3 2025 $1.07 versus $1.05. This consistency has historically driven a positive price reaction, with the stock rallying 12 % in the week following a beat and retreating 8 % after a miss. Analysts will likely scrutinize the sustainability of this pattern, especially as the company navigates margin pressures.
Market Momentum Pulse: Price performance is a barometer of market sentiment and risk appetite in the medical‑device sector. GEHC’s share price has risen 10 % over the past month and 14.5 % over three months, but it has dipped 4 % in the last six months and fallen 1 % over the past year. The recent uptick suggests short‑term optimism around new product launches, while the longer‑term decline points to broader sector headwinds such as rising interest rates and reimbursement uncertainty. A sustained positive trajectory could justify a higher valuation multiple, whereas a reversal might prompt a re‑evaluation of growth expectations. Investors should monitor the next earnings cycle for any shift in momentum.
Consensus Gap: The spread between GEHC’s current price and analyst price targets signals market expectations. With a mean target of $82.5, a high of $96, and a low of $70, the stock trades at $71.17, just above the low end of the range. This tight spread indicates that analysts are largely in agreement on a modest upside, but the narrow margin leaves little room for a significant rally. If GEHC can deliver a strong earnings beat or announce a strategic initiative that lifts the consensus, the stock could move toward the upper target. Conversely, persistent margin compression or a weak earnings beat may keep the price near the lower end.
Frequently Asked Questions About GEHC
Is GE HealthCare Technologies Inc. (GEHC) stock a good investment in 2026?
The bull case for GE HealthCare Technologies Inc. (GEHC) centers on its robust diagnostic imaging portfolio and expanding AI capabilities. Backed by a record $23.9 billion backlog, the company has demonstrated resilient earnings, with Q1 2026 EPS at $0.99 versus the $1.05 consensus and Q2 2026 EPS at $1.13 beating the $1.04 estimate. Revenue has remained around $5.3 billion, moving from $5.319 billion in Q4 2024 to $5.295 billion in Q2 2026, indicating steady demand. GEHC trades at a forward P/E of 16.3, well below its peer average of 53.0, suggesting a valuation discount. While margin pressures in the Patient Care Solutions segment pose risks, the company's investment in AI‑driven imaging and new breast ultrasound systems provides growth catalysts. Overall, GEHC offers a balanced mix of stability and innovation for investors seeking exposure to medical technology.
What drives GEHC stock price?
Primary price drivers for GEHC stem from its imaging revenue mix, AI platform adoption, and backlog momentum. The company’s recent earnings show a mix of EPS beats and revenue volatility, with Q2 2026 revenue at $5.295 billion versus a $5.369 billion target. AI initiatives, such as the newly launched breast imaging platform, are expected to lift margins and accelerate sales. Market sentiment has risen 7 points over the past 14 days, reflecting growing confidence in GEHC’s pipeline. Additionally, a forward P/E of 16.3 versus the sector average of 53.0 positions the stock as undervalued relative to peers. These factors collectively influence short‑term price movements and long‑term valuation.
Does GE HealthCare Technologies Inc. pay a dividend?
GE HealthCare Technologies Inc. (GEHC) does not currently issue a dividend, choosing instead to reinvest earnings into research and development and product expansion. This strategy supports the company’s focus on AI‑driven imaging solutions and new breast ultrasound systems. By retaining capital, GEHC aims to strengthen its backlog and capture emerging market opportunities. Investors looking for yield may find the stock more attractive for its growth potential rather than income. The absence of a dividend aligns with GEHC’s broader industry trend of prioritizing reinvestment over shareholder payouts. Consequently, dividend‑oriented investors should consider alternative holdings in the medical device sector.
How does GEHC's valuation compare to its peers?
GEHC trades at a forward price‑to‑earnings ratio of 16.3, markedly lower than the peer average of 53.0, indicating a relative valuation discount. The company’s market cap of $32.4 billion places it in the mid‑cap segment of the medical devices industry. With a 52‑week high of $89.77 and a low of $58.75, GEHC’s current price of $71.17 sits 26.4% above the low and 17.3% below the high, suggesting modest upside potential. Analyst consensus targets $82.50 on average, with a high of $96.00 and a low of $70.00, further supporting a bullish valuation outlook. In contrast, peers such as Abbott and Align trade at higher multiples, reflecting stronger growth expectations. Therefore, investors may view GEHC as a value play within a competitive landscape.
What are the key risks of buying GEHC?
Key risks for GEHC investors include margin compression in the Patient Care Solutions segment, driven by rising component costs and intense pricing competition. Regulatory scrutiny over imaging contrast media and radiopharmaceuticals could impose additional compliance burdens. The company’s revenue growth has shown volatility, with Q2 2026 revenue falling short of the $5.369 billion target. AI platform adoption remains uncertain, as market penetration may lag behind expectations. A potential divestiture of PCS assets could disrupt the revenue mix and affect cash flows. Finally, broader macroeconomic headwinds, such as rising interest rates, could dampen healthcare capital spending and impact GEHC’s sales trajectory.
How does GEHC position itself against competitors in medical devices?
GEHC differentiates itself through a comprehensive imaging ecosystem that includes CT, MR, ultrasound, and radiopharmaceuticals, complemented by AI‑enhanced diagnostic tools. The company’s recent launch of the Invenia ABUS Prime breast ultrasound system showcases its commitment to oncology imaging, a niche where competitors like Abbott have limited offerings. GEHC’s focus on digital solutions, such as its LOGIQ e platform, provides integrated workflows that attract hospital procurement teams. While larger OEMs like Siemens and Philips offer broader product lines, GEHC’s emphasis on AI and patient monitoring gives it a competitive edge in speed and accuracy. Additionally, a strong backlog of $23.9 billion underpins its market position and supports future revenue growth. Consequently, GEHC occupies a unique blend of technology leadership and clinical integration within the medical device landscape.
What is the consensus analyst price target for GEHC?
Analysts currently set an average price target of $82.50 for GEHC, with a consensus high of $96.00 and a low of $70.00. The buy‑hold‑sell split stands at 19 buys, 9 holds, and zero sells, indicating a predominantly bullish stance. This target reflects optimism around GEHC’s AI initiatives and backlog strength. The high target aligns with the upper end of the 52‑week range, while the low target sits near the current price, offering a realistic upside range. Market sentiment has risen, reinforcing the positive outlook. Investors should weigh the target against the company’s valuation discount relative to peers.
How has GEHC performed in recent earnings?
In Q1 2026, GEHC reported EPS of $0.99 versus the $1.05 consensus, missing on earnings, while revenue reached $5.131 billion against a $5.028 billion estimate. The following quarter, Q2 2026, saw an EPS of $1.13 beating the $1.04 forecast, but revenue slipped to $5.295 billion from the $5.369 billion target. Historically, the company has delivered EPS beats in most quarters, with Q4 2025 EPS at $1.44 versus $1.43 estimate, though revenue in that period fell slightly below the $5.723 billion forecast. This pattern of EPS resilience amid revenue volatility underscores GEHC’s ability to manage costs while navigating market pressures. The earnings guidance for the next quarter remains unchanged, maintaining a focus on AI product uptake. Overall, the earnings trajectory reflects both strength and areas for improvement.
What does GEHC's recent stock price performance look like?
Over the past month, GEHC has posted a 10% return, while the three‑month performance climbed 14.5%. However, the six‑month return dipped 4%, and the one‑year return stands at a modest -1%. These figures suggest a recent rally that may be stabilizing, as the stock trades near the upper end of its 52‑week range. Market sentiment has risen by 7 points in the last two weeks, reflecting growing confidence in GEHC’s pipeline. The price volatility remains moderate, with a current price of $71.17 hovering 26.4% above the 52‑week low. Investors should monitor the stock’s trajectory relative to its valuation multiples and peer benchmarks.
How has GEHC's revenue trended over the past quarters?
Quarterly revenue has hovered around $5.3 billion, moving from $5.319 billion in Q4 2024 to $5.295 billion in Q2 2026, indicating a modest contraction amid pricing pressures. In Q1 2026, revenue reached $5.131 billion, beating the $5.028 billion estimate, while Q2 2026 revenue fell to $5.295 billion from the $5.369 billion target. The company’s revenue mix remains heavily weighted toward imaging systems, with recent launches in breast ultrasound and AI‑driven platforms contributing to growth. Despite slight quarterly declines, the backlog of $23.9 billion provides a cushion for future revenue generation. Revenue trends suggest that GEHC is maintaining scale while navigating market headwinds. Continued focus on high‑margin AI products may help reverse the downward drift in the near term.
What impact does GEHC's $23.9B backlog have on its outlook?
A record $23.9 billion backlog signals strong demand for GEHC’s diagnostic imaging and patient monitoring solutions. The backlog translates into a projected revenue stream that exceeds the company’s current quarterly earnings, providing a buffer against short‑term market volatility. However, converting backlog into cash depends on the pace of order fulfillment and the ability to manage margin compression in the Patient Care Solutions segment. The backlog also supports GEHC’s strategy to invest in AI‑driven imaging, as a larger order base justifies capital expenditures. Analysts view the backlog as a positive catalyst, reflected in the upward revision of the price target to $85 from $80. Nonetheless, any slowdown in healthcare capital spending could reduce backlog growth and impact future earnings.
How is GEHC leveraging AI in its imaging portfolio?
GEHC is embedding AI across its CT and MR workflows to accelerate diagnosis and reduce scan times, positioning itself at the forefront of precision imaging. The company recently introduced an AI‑driven breast imaging platform that automates image analysis and improves detection rates. AI integration also extends to patient monitoring, where predictive analytics help clinicians intervene earlier. By combining hardware with software, GEHC offers a differentiated ecosystem that attracts hospitals seeking end‑to‑end solutions. The AI strategy is expected to lift margins, as software licensing and subscription models generate recurring revenue. Market reception has been positive, with analysts upgrading their outlooks following the AI announcements.
Learn More
Breakouts, Stops & Retracements: The Institutional Trading Framework Master breakout confirmation, volume analysis, volatility filters, ATR methods, pivot techniques, anticipation signals, and professional stop-loss management.
What Is EMA and How to Read It Learn how the Exponential Moving Average helps you identify trend direction, momentum shifts, and dynamic support or resistance.
Dow Theory History, Theorems, Trends, Confirmation, Volume & Criticisms A comprehensive and original deep dive into Dow Theory, including its historical roots, core theorems, trend classifications, confirmation principles, volume interpretation, criticisms, and modern relevance.
What Is RSI and How to Read It Learn how the Relative Strength Index helps you measure momentum and identify overbought or oversold conditions.
Trend Lines in Technical Analysis: The Complete Institutional Guide Master trend lines, accelerating and decelerating structures, channels, log scale, Pitchfork, Gann fans, and professional breakout confirmation.
Bar Chart Patterns: Complete Guide to Structure, Breakouts, Retests, and Reliability Master bar chart patterns from boundary definition to breakout confirmation. Learn frequency vs reliability across timeframes, pullbacks/throwbacks, measured moves, and the behavioral traps that create false pattern signals.
Recent News Coverage
Most recent articles, ranked by recency (click to expand).